[1]国家肿瘤质控中心乳腺癌专家委员会, 中国抗癌协会肿瘤药物临床研究专业委员会. CDK4/6 抑制剂治疗激素受体阳性人表皮生长因子受体 2 阴性乳腺癌临床应用专家共识 (2023 版)[J]. 中华肿瘤杂志, 2023, 45(12):1003-1017.[2]Gabriel N. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-950.[3]Finn RS. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936.[4]Johnston S. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019 Jan 17;5:5.[5]Zhang P. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):646-657.[6]Joyce O’shaughnessy. Efficacy and safety of first-line ribociclib+letrozole in patients with de novo metastatic disease and late recurrence from (neo)adjuvant therapy in MONALEESA-2.2023 ASCO 196P.[7]Hortobagyi GN. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748.[8]Tripathy D. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915.[9]Im SA. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316.[10]《中国临床肿瘤学会（CSCO）乳腺癌诊疗指南（2024 年版）》[11]徐兵河. CDK4/6 抑制剂治疗激素受体阳性人表皮生长因子受体 2 阴性晚期乳腺癌的进展与未来 [J]. 中华肿瘤杂志, 2021, 43(4):431-442.
